4D Molecular Therapeutics (FDMT) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($870.8 million vs $701.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | ODTX |
|---|---|---|
| Share price | $12.70 | $18.12 |
| Market cap | $701.60M | $870.82M |
| 1-day change | +0.87% | +0.22% |
| YTD return | +69.33% | — |
| 1-year return | +31.47% | — |
| 5-year return | -53.51% | — |
| EPS (TTM) | $-2.63 | $-7.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $29.05 |
| 52-week low | $6.96 | $15.10 |
| Distance from 52-week high | -24.99% | -37.62% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +121.18% | +97.30% |
| Average volume | 926.78K | 274.77K |
| Shares outstanding | 55.24M | 48.06M |
| Employees | 196 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
FDMT vs ODTX FAQ
Which is bigger, 4D Molecular Therapeutics or Odyssey Therapeutics?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $870.82M compared with $701.60M for 4D Molecular Therapeutics (FDMT).
Are 4D Molecular Therapeutics and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.